Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues
Reexamination Certificate
2007-10-31
2010-10-19
Rawlings, Stephen L (Department: 1643)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
C536S023500
Reexamination Certificate
active
07816493
ABSTRACT:
Disclosed herein is the discovery of a soluble MN/CA IX (s-CA IX) found in body fluids, such as, urine and serum. Soluble CA IX comprises the extracellular domain of CA IX or portions thereof. The predominant s-CA IX species is the extracellular domain comprising a proteoglycan-like (PG) domain and carbonic anhydrase (CA) domain, and having a molecular weight of about 50/54 kilodaltons. Diagnostic/prognostic methods for precancer/cancer that detect or detect and quantitate s-CA IX in body fluids, are described. Also disclosed is the coexpression of CA IX and HER-2 that provides potentially synergistic diagnostic/prognostic and therapeutic strategies for precancer/cancer. Further disclosed are new MN/CA IX-specific antibodies generated from MN/CA IX-deficient mice, useful diagnostically/prognostically and therapeutically for cancer/precancer. Preferred are new antibodies, specific for non-immunodominant epitopes of MN/CA IX, useful to detect soluble CA IX (s-CA IX) in body fluids, preferably in combination with antibodies specific to immunodominant epitopes of MN/CA IX.
REFERENCES:
patent: 4968603 (1990-11-01), Slamon et al.
patent: 5387676 (1995-02-01), Zavada et al.
patent: 5401638 (1995-03-01), Carney et al.
patent: 5955075 (1999-09-01), Zavada et al.
patent: 5972353 (1999-10-01), Zavada et al.
patent: 5981711 (1999-11-01), Zavada et al.
patent: 5989838 (1999-11-01), Zavada et al.
patent: 6004535 (1999-12-01), Zavada et al.
patent: 6027887 (2000-02-01), Zavada et al.
patent: 6051226 (2000-04-01), Zavada et al.
patent: 6069242 (2000-05-01), Zavada et al.
patent: 6093548 (2000-07-01), Zavada et al.
patent: 6204370 (2001-03-01), Zavada et al.
patent: 6297041 (2001-10-01), Zavada et al.
patent: 6297051 (2001-10-01), Zavada et al.
patent: 6770438 (2004-08-01), Zavada et al.
patent: 6774117 (2004-08-01), Zavada et al.
patent: WO 93/18152 (1993-09-01), None
patent: WO 95/34650 (1995-12-01), None
patent: WO 00/24913 (2000-05-01), None
patent: WO 2004/017923 (2004-03-01), None
patent: WO 2008/103327 (2008-08-01), None
Roessler et al. (Mol. Cell. Prot. 2006; 5 (11): 2092-21).
Roessler et al. (Clin. Can. Res. 2005; 11 (18): 6550-6557).
Zolg et al. (Mol. Cell. Prot. 2004; 3 (4): 345-354).
Brewer et al. (Gynecol. Oncol. Dec. 1996; 63 (3): 337-344).
Zhou et al. (Urology. Feb. 2010; 75 (2): 257-61).
Zavada et al. (Br. J. Cancer. Sep. 2003; 89 (15): 1067-71).
Hyrsl et al. (Neoplasma. 2009; 56 (4): 298-302).
Li et al. (Biochem Biophys Res Commun. Aug. 28, 2009; 386 (3): 488-92).
Airley et al., “Glucose Transporter Glut-1 Expression Correlates with Tumor Hypoxia and Predicts Metastasis-free Surival in Advanced Carcinoma on the Cervix,”Clinical Cancer Research, 7:928-934 (Apr. 2001).
Bander et al., “Renal cancer imaging with monoclonal antibody G250,”J. Urol., 155 (5 Suppl.): 583A (Abstract 1088) (1996).
Chia et al., “Prognostic significance of a novel hypoxia-regulated marker, carbonic anhydrase IX, in invasive breast carcinoma,”J. Clin. Oncol., 19(16): 3360-3668 (Aug. 15, 2001).
Giatromanolaki et al., “Expression of Hypoxia-inducible Carbonic Anhydrase-9 Relates to Angiogenic Pathways and Independently to Poor Outcome in Non-Small Cell Lung Cancer,”Cancer Research, 61(21): 7992-7998 (Nov. 1, 2001).
Griffiths et al., “The macrophate—a novel system to deliver gene therapy to pathological hypoxia,”Gene Therapy, 7: 255-262 (2000).
Horton, J., “Trastuzumab Use in Breast Cancer: Clinical Issues,”Cancer Control, 9(6): 499-507 (2002).
Ivanov et al., “Expression of Hypoxia-Inducible Cell-Surface Transmembrane Carbonie Anhydrases in Human Cancer,”American Journal of Pathology, 158(3): 905-919 (Mar. 2001).
Kaluz et al., “Lowered Oxygen Tension Induces Expression of the Hypoxia Marker MN/Carbonic Anhydrase IX in the Absence of Hypoxia-inducible Factor 1 Stabilization: A Role for Phosphatidylinositol 3′-Kinase,”Cancer Research, 62: 4469-4477 (Aug. 1, 2002).
Kivela et al., “Expression of transmembrane carbonic anhydrase Isoenzymes IX and XII in normal human pancreas and pancreatic tumours,”Histochemistry and Cell Biology, 114(3): 197-204 (2000).
Kuter, I., “Breast Cancer,”The Oncologist, 6: 338-346 (2001).
Lieskovska et al., “Study of in vitro conditions modulating expression of MN/CA IX protein in human cell lines dervived from cervical carcinoma,”Neoplasma, 46(1): 17-24 (1999).
Loncaster et al., “Carbonic Anhydrase (CA IX) Expression, a Protential New Intrinsic Marker of Hypoxia: Correlations with Tumor Oxygen Measurements and Prognosis in Locally Advanced Carcinoma of the Cervix,”Cancer Res, 61(17): 6394-6399 (Sep. 1, 2001).
Oosterwijk and Debruyne, “Radiolabeled monoclonal antibody G250 in renal-cell carcinoma,”World Journal of Urology, 13: 186-190 (1995).
Opavsky et al., “Human MN/CA9 Gene a Novel Member of the Carbonic Anhydrase Family: Structure and Exon to Protein Domain Relationships,”Genomics, 33: 480-487 (1996).
Parkkila et al., “Carbonic anhydrase inhibitor suppresses invasion of renal cancer cells in vitro,”PNAS(USA), 97(5): 2220-2224 (Feb. 29, 2000).
Pastorek et al., “Cloning and characterization of MN, a human tumor-associated protein with a domain homologous to carbonic anhydrase and a putative helix-loop-helix DNA binding segment,”Oncogene, 9: 2877-2888 (1994).
Pastorekova et al., “A Novel Quasi-viral Agent, MaTu, Is a Two-Component System,”Virology, 187: 620-626 (1992).
Pastorekova et al., “Carbonic Anhydrase IX, MN/CA IX: Analysis of Stomach Complementary DNA Sequence and Expression in Human and Rat Alimentary Tracts,”Gastroenterology, 112: 398-408 (1997).
Revillion et al., “ERBB2Oncogene in Human Breast Cancer and its Clinical Sigificance,”Euro J. Cancer, 34: 791-808 (1998).
Steffens et al., “Targeting of Renal Cell Carcinoma with Iodine-131-Labeled Chimeric Monoclonal Antibody G250,”Journal of Clinical Oncology, 15(4): 1529-1537 (Apr. 1997).
Steffens et al., “Radioimmunotherapy with 1311-cG250 Monoclonal antibody in Patients with Metastasized RCC, Phase I/II Study,”Journal of Urology, 159 (5 Suppl.): Abstract No. 562 (May 1998).
Teicher et al., “A Carbonic Anhydrase Inhibitor as a Potential Modulator of Cancer Therapies,”Anticancer Research, 13: 1549-1556 (1993).
Trikha et al., “Monoclonal antibodies as therapeutics in oncology,”Current Opinion in Biotechnology, 13(6): 609-614 (2002).
Turner et al., “MN Antigen Expression in Normal Prencoplastic, and Neoplastic Esophagus: a Clinicopathological Study of a New Cancer-Associated Biomarker,”Hum. Pathol., 28(6): 740-744 (Jun. 1997).
Uemura et al., “MN/CA IX/G250 as a potential target for immunotherapy of renal cell carcinomas,”Br. J. Cancer, 81(4): 741-746 (Oct. 1999).
Uemura et al., “MN Target Immunotherapy for Renal Cell Carcinoma,”Journal of Urology, 159 (5 Suppl.): 188, Abstract No. 724 (May 1998).
Vaupel and Hoeckel, “Predictive Power of the Tumor Oxygenation Status,”Adv. Exp. Med. Biol., 471: 533-539 (1999).
Von Mehren et al., “Monoclonal Antibody Therapy for Cancer,”Annu. Rev. Med., 54: 343-369 (2003).
Watson et al., “Carbonic anhydrase XII is a marker of good prognosis in invasive breast carcinoma,”Br. J. Cancer, 88(7): 1065-1070 (2003).
Wingo et al., “The Catalytic Properties of Human Carbonic Anhydrase IX,”Biochemical and Biophysical Research Communications, 288: 666-669 (2001).
Wykoff et al., “Hypoxia-inducible Expression of Tumor-associated Carbonic Anhydrases,”Cancer Research, 60: 7075-7083 (Dec. 15, 2000).
Wykoff et al., “Expression of the hypoxia-inducible and tumor-associated carbonic anhydrases in ductal carcinoma in situ of the breast,”Am. J. Pathol., 158(3): 1011-1019 (Mar. 2001).
Zavada et al., “Expression of MaTu-MN Protein in Human Tumor Cultures and in Cli
Gut Marta Ortova
Pastorek Jaromir
Pastorekova Silvia
Zatovicova Miriam
Zavada Jan
Harland Joan C.
Institute of Virology of the Slovak Academy of Sciences
Lauder Leona L.
Rawlings Stephen L
Shimei Barbara A.
LandOfFree
Soluble form of carbonic anhydrase IX (S-CA IX), assays to... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Soluble form of carbonic anhydrase IX (S-CA IX), assays to..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Soluble form of carbonic anhydrase IX (S-CA IX), assays to... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4239152